Spain faces shortages of menopause hormone replacement therapies

Spain is experiencing supply shortages of various hormone replacement therapies (HRT) used to treat menopause, premature ovarian failure, and for transgender women. The shortage has caused concern among patients who have had to switch brands or administration methods multiple times, increasing the risk of treatment abandonment.

Silvia P. González, president of the Spanish Association for the Study of Menopause (AEEM), noted that while the situation is causing significant anxiety, the shortage is considered transitory. According to the Spanish Agency of Medicines and Medical Products (Aemps), most missing drugs are expected to return to pharmacies between October and November.

Medical professionals highlight a significant gap in treatment access: while approximately 50% of women may require hormone therapy, only about 7% currently receive it. Experts suggest that historical hesitations to prescribe HRT, stemming from studies two decades ago, have contributed to lower prescription rates. The AEEM is working to improve diagnosis and support through specialized working groups and tools to help clinicians and patients manage the climacteric transition.